LAUSR

Key Points Question Is the use of cimetropium bromide, an antispasmodic agent, associated with higher rates of detection of gastric neoplasms during esophagogastroduodenoscopy (EGD) screening? Findings In this cohort study of 67 683 participants who received EGD screening, the use of cimetropium bromide as premedication was associated with higher gastric neoplasm detection rates during EGD than nonuse. Lesions in the gastric body were detected more frequently in those who received cimetropium bromide compared with those who did not. Meaning This study’s findings suggest that cimetropium bromide may be considered as premedication for the detection of gastric neoplasms during EGD examination among individuals with no contraindications.